3 August 2026
Casgevy sales jump as CRISPR pipeline enters more first-in-human work
On Aug. 3, 2026, CRISPR Therapeutics reported $76 million in second-quarter Casgevy revenue and new Phase 1 starts for CTX340 and CTX460.
The full briefing is in the app.